SAN DIEGO, Aug. 7, 2019 /PRNewswire/ -- Shareholder Rights
Law Firm Johnson Fistel, LLP, is investigating potential claims
against Novartis AG ("Novartis") (NYSE: NVS) for violations of
federal securities laws.
On August 7, 2019, Novartis made
known that it knew about discrepancies in data it submitted to
regulators as it sought approval of its gene therapy drug
Zolgensma, but delayed notifying authorities until it completed an
internal investigation.
Novartis faces possible penalties from the FDA. On August 6, 2019, the FDA said the company was
aware of the problems for as much as two months before the drug's
U.S. approval.
If you recently purchased Novartis and lost money, realized
or unrealized on your investment, and are interested in
learning more about the investigation or your legal rights and
remedies, please contact Jim Baker
(jimb@johnsonfistel.com) by email or phone at 619-814-4471. If
emailing, please include a phone number.
Additionally, you can [click here to join this
action]. There is no cost or obligation to you.
About Johnson Fistel,
LLP:
Johnson Fistel, LLP is a nationally
recognized shareholder rights law firm with offices in California, New
York, and Georgia. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit
http://www.johnsonfistel.com. Attorney advertising. Past results do
not guarantee future outcomes.
Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com
[click here to join this action]
View original
content:http://www.prnewswire.com/news-releases/novartis-nvs-alert-johnson-fistel-launches-investigation-into-novartis-ag-investors-encouraged-to-contact-firm-300898453.html
SOURCE Johnson Fistel, LLP